TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25528523
Drug: Single-dose vaccination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose vaccination
Study: 25528523
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses in lifetime
Study: 21716073
Drug: Dolutegravir 10
Normalized name: dolutegravir 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolutegravir 10 mg
Study: 23807273
Drug: Dolutegravir 25
Normalized name: dolutegravir 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolutegravir 25 mg
Study: 23807273
Drug: Efavirenz (control)
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Efavirenz (control) 600 mg
Study: 23807273
Drug: All DTG
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All DTG treatment groups combined
Study: 17520463
Drug: Etanercept (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept (2 x 50 mg/week)
Study: 17520463
Drug: Etanercept (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept (2 x 25 mg/week)
Study: 8134674
Drug: Thiopental (4‐6.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental (4‐6.5 mg/kg)
Study: 8134674
Drug: Propofol (1.5‐2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (1.5‐2.5 mg/kg)
Study: 8134674
Drug: Both induction
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both induction agents
Study: 27473135
Drug: 0.45 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.45 mg/d oral conjugated equine estrogens (CEE)
Study: 27473135
Drug: 50 μg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 μg/d transdermal 17β‐estradiol
Study: 18082886
Drug: Evening-dosed latanoprost/timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evening-dosed latanoprost/timolol fixed combination
Study: 11226091
Drug: Dexamethasone 0.5
Normalized name: dexamethasone 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 0.5 mg/kg IV preoperatively
Study: 2419019
Drug: inosine pranobex
Normalized name: inosine pranobex
DrugBank: Inosine pranobex (DB13156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: inosine pranobex (INPX) 3 g/day
Study: 28552331
Drug: Neurofeedback therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurofeedback therapy (NFT) for 20 sessions over four weeks
Study: 25837528
Drug: Methadone (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone (0.3 mg/kg)
Study: 25837528
Drug: Fentanyl (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (12 μg/kg)
Study: 9766410
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate (MgSO4) administration at birth (6 mg/kg elemental magnesium)
Study: 7816872
Drug: Active drug
Normalized name: Capillary active drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active drug (15 mg males, 10 mg females)
Study: 7816872
Drug: Rectal suppository
Normalized name: Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal suppository (2.5 mg b.i.d. for 3 days)
Study: 7816872
Drug: Oral capsule
Normalized name: Oral Capsule
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral capsule (chronic dosing)
Study: 7816872
Drug: Inhalation (acute
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation (acute dosing)
Study: 7816872
Drug: Oral and
Normalized name: Tridate, oral and rectal kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral and sublingual routes (acute dosing)
Study: 7816872
Drug: Fasted and
Normalized name: norgestimate and ethinylestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasted and fed states (oral dose)
Study: 3047526
Drug: 10 mg/day
Normalized name: Adlarity 10 MG/Day Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/day dydrogesterone continuously
Study: 3047526
Drug: 20 mg/day
Normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/day dydrogesterone for the first 12 days of each month
Study: 3047526
Drug: 0.625 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg/day conjugated oestrogen continuously
Study: 28005194
Drug: Dapsone 7.5%
Normalized name: DAPSONE 7.5% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapsone 7.5% gel
Study: 24369764
Drug: Exenatide twice
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide twice daily (BID)
Study: 26134916
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine once daily (QD)
Study: 19706374
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (CR, 4x5 g/day creatine monohydrate for 5 days)
Study: 19706374
Drug: Placebo (P,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (P, same dose of a dextrose‐ascorbic acid placebo)
Study: 17087116
Drug: Allergen vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allergen vaccine atomization inhalation (A group)
Study: 17087116
Drug: Sublingual allergen
Normalized name: American house dust mite allergenic extract / European house dust mite allergenic extract Sublingual Tablet [Odactra]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual allergen vaccine (B group)
Study: 17087116
Drug: Hypodermic injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypodermic injection (C group)
Study: 11396751
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25% bupivacaine 0.5 ml/kg (group B)
Study: 11396751
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25% bupivacaine 0.5 ml/kg with 50 microg/kg midazolam (group BM)
Study: 2772858
Drug: Allergen inhalation
Normalized name: catfish allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allergen inhalation challenge
Study: 29121999
Drug: Treatment partner
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment partner and psychoeducation intervention
Study: 16566675
Drug: COLD-fX (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: COLD-fX (200 mg/capsule, 2 capsules/day)
Study: 11571330
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine patches (17.5 mg in the first week, 35.0 mg in the second and third weeks)
Study: 7923961
Drug: Steroids or
Normalized name: Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroids or a combination of steroids and cytotoxic therapy
Study: 3392755
Drug: Reduced Environmental
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced Environmental Stimulation Therapy (REST) with anti-alcohol messages for 2.5 hours
Study: 3392755
Drug: Reduced Environmental
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced Environmental Stimulation Therapy (REST) with revised anti-alcohol message for 2.5 hours
Study: 28095412
Drug: Intensive lipid
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive lipid lowering (target LDL-cholesterol <1.3 mmol/l)
Study: 28095412
Drug: Guideline lipid
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline lipid lowering (target LDL-c <3.0 mmol/l)
Study: 28095412
Drug: Intensive lipid
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive lipid lowering therapy
Study: 28095412
Drug: Guideline lipid
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline lipid lowering therapy
Study: 21492255
Drug: 1.5 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg/kg/day of liposomal amphotericin B for 5 days
Study: 17573730
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) with standardized cat dander extract
Study: 15367188
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (no Emdogain application)
Study: 7628832
Drug: Insulin (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin (0.15 IU insulin/kg body weight) to induce hypoglycemia
Study: 2699072
Drug: Radical radiation
Normalized name: Campsis radicans flower extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radical radiation therapy (60 Gy) and salvage cystectomy
Study: 21304241
Drug: Lansoprazole 15
Normalized name: lansoprazole 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 15 mg (half-dose)
Study: 21304241
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg (standard-dose)
Study: 15028562
Drug: Montelukast plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast plus Fluticasone propionate (10 mg + 440 microg/day)
Study: 9272100
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) replacement therapy (2 IU/m2)
Study: 6815696
Drug: 6-azamianserin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-azamianserin (2 mg)
Study: 6815696
Drug: mianserin (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: mianserin (6 mg)
Study: 6815696
Drug: flurazepam (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: flurazepam (10 mg)
Study: 6815696
Drug: 6-azamianserin (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-azamianserin (0.5 and 1.0 mg of (+) and (‐) enantiomers)
Study: 31919289
Drug: NICU music
Normalized name: Nicumalon
DrugBank: Acenocoumarol (DB01418)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NICU music therapy intervention, Multimodal Neurologic Enhancement
Study: 30489382
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg of oral ropinirole twice daily added on to current medication
Study: 30489382
Drug: Placebo twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo twice daily added on to current medication
Study: 18757262
Drug: Fulvestrant loading
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fulvestrant loading dose regimen (500 mg on day 0, 250 mg on days 14 and 28, then 250 mg each month thereafter)
Study: 18757262
Drug: Fulvestrant loading
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fulvestrant loading dose regimen
Study: 9187987
Drug: Cardiopulmonary bypass
Normalized name: factor VIII inhibitor bypassing activity
DrugBank: Anti-inhibitor coagulant complex (DB13151)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiopulmonary bypass (CPB) flow rate of 2.3 L/min/m2
Study: 9187987
Drug: Cardiopulmonary bypass
Normalized name: factor VIII inhibitor bypassing activity
DrugBank: Anti-inhibitor coagulant complex (DB13151)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiopulmonary bypass (CPB) flow rate of 1.2 L/min/m2
Study: 3890463
Drug: Daily whole
Normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily whole body soap wash and umbilical cleansing with 4% chlorhexidine detergent solution (Hibiscrub)
Study: 3890463
Drug: Daily whole
Normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily whole body soap wash and umbilical cleansing with benzine solution
Study: 3890463
Drug: Daily whole
Normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily whole body soap wash and umbilical cleansing with 0.05% chlorhexidine
Study: 3890463
Drug: Daily whole
Normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily whole body soap wash (control group)
Study: 26951414
Drug: Mindfulness‐Based Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness‐Based Therapy for Insomnia (MBTI)
Study: 17305624
Drug: Electrostimulation using
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrostimulation using a device mounted on an individualized intra‐oral removable appliance for 10 minutes.
Study: 15117900
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist leuprolide acetate followed by recombinant human FSH (r-hFSH; 100 IU/day) and hCG (2000 IU/twice a week) for 2 months (Group A1 and B1)
Study: 7506160
Drug: nimesulide (200mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: nimesulide (200mg 3 times daily)
Study: 7506160
Drug: diclofenac (100mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: diclofenac (100mg 3 times daily)
Study: 3552694
Drug: Single-dose fosfomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose fosfomycin trometamol (3 g)
Study: 3552694
Drug: Pipemidic acid
Normalized name: pipemidic acid
DrugBank: Pipemidic acid (DB13823)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pipemidic acid (200-gram doses b.i.d. for 7 days)
Study: 23558093
Drug: Deleobuvir 400
Normalized name: Deleobuvir
DrugBank: Deleobuvir (DB14850)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deleobuvir 400 mg three times daily plus faldaprevir 120 mg once daily and weight-based ribavirin for 4 weeks
Study: 23558093
Drug: Deleobuvir 600
Normalized name: Deleobuvir
DrugBank: Deleobuvir (DB14850)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deleobuvir 600 mg three times daily plus faldaprevir 120 mg once daily and weight-based ribavirin for 4 weeks
Study: 21234767
Drug: 0.125 mg/kg/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125 mg/kg/min landiolol
Study: 21234767
Drug: 0.25 mg/kg/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg/kg/min landiolol
Study: 18445733
Drug: Teaching a
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teaching a new word (e.g. 'whisk') paired with a novel picture, repeated exposure not specified.
Study: 8232927
Drug: Sensory stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sensory stimulation (acupuncture) twice a week for 10 weeks
Study: 8232927
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving daily physiotherapy and occupational therapy
Study: 30624092
Drug: OFD +
Normalized name: OFDZ
DrugBank: Oxfendazole (DB11446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OFD + L-PRF
Study: 26242112
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy combined with Chinese medicine (CM)
Study: 16890064
Drug: Morphine Ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine Ondansetron PCA
Study: 14693593
Drug: 2-chloroprocaine with
Normalized name: 2-chloroprocaine
DrugBank: Chloroprocaine (DB01161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2-chloroprocaine with fentanyl (20 micro g)
Study: 11527621
Drug: Mild renal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mild renal insufficiency (creatinine 1.2 mg/dl to 1.4 mg/dl)
Study: 11527621
Drug: Moderate renal
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate renal insufficiency (creatinine >1.4 mg/dl)
Study: 11527621
Drug: Normal renal
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal renal function (creatinine < 1.2 mg/dl)
Study: 9000046
Drug: Nonpharmacological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonpharmacological treatment for CFS
Study: 3727591
Drug: 13% maltodextrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13% maltodextrin solution (52 kcal, 160 mOsm/l)
Study: 19025038
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with no special treatment
Study: 12521598
Drug: Topical alpha-tocotrienol
Normalized name: .ALPHA.-TOCOTRIENOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical alpha-tocotrienol (5% w/vol)
Study: 8713558
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg alfuzosin
Study: 8713558
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg alfuzosin
Study: 8713558
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg alfuzosin
Study: 1854053
Drug: Additional dose
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional dose of propofol (0.7 mg.kg‐1) in group P2
Study: 1854053
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose of propofol (1.5 mg.kg‐1) in group P1
Study: 25180056
Drug: Melatonin 2
Normalized name: melatonin 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 2 mg twice per day
Study: 25180056
Drug: Melatonin 4
Normalized name: vit B/folic acid/calcium/soy xt/black cohosh xt/melatonin 400 mcg-125 mg-62 mg-40 mg (day)/175 mg-62 mg-1 mg (night) ORAL CAPSULE, SEQUENTIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 4 mg twice per day
Study: 25180056
Drug: Melatonin 8
Normalized name: Calcium Carbonate/Melatonin 84 MG-5 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 8 mg twice per day
Study: 21965229
Drug: Nonstandardised antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonstandardised antibiotic therapy (control)
Study: 21965229
Drug: β-lactam plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: β-lactam plus macrolide combination (BLM)
Study: 17094530
Drug: Intravenous diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous diazepam (1 mg/kg)
Study: 11321236
Drug: GM-CSF (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM-CSF (80 microg or 250 microg) administered as a single injection with the first and second doses of hepatitis B vaccine
Study: 11321236
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine administered at 0, 1, and 6 months
Study: 3137632
Drug: 5-methoxypsoralen (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-methoxypsoralen (40 mg daily at 9 p.m.)
Study: 31820602
Drug: Acupuncture at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture at 'three points of iliolumbar' combined with celecoxib (200 mg once a day for 3 days)
Study: 31820602
Drug: Celecoxib alone
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib alone (200 mg once a day for 3 days)
Study: 20702523
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) treatment for 12 months
Study: 23436915
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) treatment for 24 months
Study: 18959591
Drug: Hydro-alcoholic solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydro-alcoholic solution of a phytocompound (20 gtt 30 min before meals for 2 weeks)
Study: 12043864
Drug: ProFile Ni‐Ti.06
Approvals — FDA: no, EMA: no, PMDA: no
Description: ProFile Ni‐Ti.06 taper Series 29
Study: 9821653
Drug: Conventional capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional capsules in humans
Study: 9821653
Drug: Enteric coated
Normalized name: Mesasal Enteric Coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric coated tablets in humans
Study: 9821653
Drug: Conventional capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional capsules in dogs (pentagastrin pretreated)
Study: 9821653
Drug: Conventional capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional capsules in dogs (saline pretreated)
Study: 7666816
Drug: Transdermal oestradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal oestradiol patch (50 micrograms daily) + levonorgestrel-releasing IUD (20 micrograms daily)
Study: 7666816
Drug: Oral therapy
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral therapy (2 mg of estradiol + 1 mg of noretisterone acetate daily)
Study: 2757882
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release acetazolamide (SRA) 500 mg once or twice daily
Study: 2757882
Drug: Conventional acetazolamide
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional acetazolamide (CA) 500 mg once or twice daily
Study: 772394
Drug: Mesterolone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesterolone (2 mg/kg orally for 6 months)
Study: 24661263
Drug: Fluoxetine and
Normalized name: fluoxetine and psycholeptics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine and Cognitive-Behavioral Therapy (CBT)
Study: 21753776
Drug: Lactotripeptides (LTPs)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactotripeptides (LTPs) at 3 mg per day for 6 weeks
Study: 19005687
Drug: 1.0 g
Normalized name: IODINE 11.0 g in 1 L TOPICAL SOLUTION [T.D.]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 g ginger daily
Study: 19005687
Drug: 2.0 g
Normalized name: Fifty50 2.0 Glucose Meter
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 g ginger daily
Study: 16849757
Drug: Oral fenretinide
Normalized name: FENRETINIDE
DrugBank: Fenretinide (DB05076)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fenretinide at 2,475 mg/m2 per day for 7 days, repeated every 21 days.
Study: 16849757
Drug: Oral fenretinide
Normalized name: FENRETINIDE
DrugBank: Fenretinide (DB05076)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fenretinide at 3,300 mg/m2 per day (highest dose tested).
Study: 16849757
Drug: Oral fenretinide
Normalized name: FENRETINIDE
DrugBank: Fenretinide (DB05076)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fenretinide at 1,050 mg/m2.
Study: 16849757
Drug: Oral fenretinide
Normalized name: FENRETINIDE
DrugBank: Fenretinide (DB05076)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fenretinide at 1,860 mg/m2.
Study: 16849757
Drug: Oral fenretinide
Normalized name: FENRETINIDE
DrugBank: Fenretinide (DB05076)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fenretinide at 2,475 mg/m2.
Study: 9221964
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIg; 2g/kg and then 1 g/kg every three weeks)